JP7890196B2 - ヒト対象の組織におけるエーテル脂質分子の混合物を維持または調節するための組成物 - Google Patents

ヒト対象の組織におけるエーテル脂質分子の混合物を維持または調節するための組成物

Info

Publication number
JP7890196B2
JP7890196B2 JP2022503457A JP2022503457A JP7890196B2 JP 7890196 B2 JP7890196 B2 JP 7890196B2 JP 2022503457 A JP2022503457 A JP 2022503457A JP 2022503457 A JP2022503457 A JP 2022503457A JP 7890196 B2 JP7890196 B2 JP 7890196B2
Authority
JP
Japan
Prior art keywords
ether
group
composition
ether lipid
alkyl
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Active
Application number
JP2022503457A
Other languages
English (en)
Japanese (ja)
Other versions
JP2022541277A5 (cg-RX-API-DMAC10.html
JP2022541277A (ja
Inventor
ピーター・ジョン・ミクル
Original Assignee
ベイカー ハート アンド ダイアビーティス インスティテュート
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Priority claimed from AU2019902527A external-priority patent/AU2019902527A0/en
Application filed by ベイカー ハート アンド ダイアビーティス インスティテュート filed Critical ベイカー ハート アンド ダイアビーティス インスティテュート
Publication of JP2022541277A publication Critical patent/JP2022541277A/ja
Publication of JP2022541277A5 publication Critical patent/JP2022541277A5/ja
Application granted granted Critical
Publication of JP7890196B2 publication Critical patent/JP7890196B2/ja
Active legal-status Critical Current
Anticipated expiration legal-status Critical

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/21—Esters, e.g. nitroglycerine, selenocyanates
    • A61K31/215—Esters, e.g. nitroglycerine, selenocyanates of carboxylic acids
    • A61K31/22—Esters, e.g. nitroglycerine, selenocyanates of carboxylic acids of acyclic acids, e.g. pravastatin
    • A61K31/23—Esters, e.g. nitroglycerine, selenocyanates of carboxylic acids of acyclic acids, e.g. pravastatin of acids having a carboxyl group bound to a chain of seven or more carbon atoms
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/66—Phosphorus compounds
    • A61K31/661—Phosphorus acids or esters thereof not having P—C bonds, e.g. fosfosal, dichlorvos, malathion or mevinphos
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/21—Esters, e.g. nitroglycerine, selenocyanates
    • A61K31/215—Esters, e.g. nitroglycerine, selenocyanates of carboxylic acids
    • A61K31/22—Esters, e.g. nitroglycerine, selenocyanates of carboxylic acids of acyclic acids, e.g. pravastatin
    • A—HUMAN NECESSITIES
    • A23—FOODS OR FOODSTUFFS; TREATMENT THEREOF, NOT COVERED BY OTHER CLASSES
    • A23C—DAIRY PRODUCTS, e.g. MILK, BUTTER OR CHEESE; MILK OR CHEESE SUBSTITUTES; PREPARATION THEREOF
    • A23C9/00—Milk preparations; Milk powder or milk powder preparations
    • A23C9/152—Milk preparations; Milk powder or milk powder preparations containing additives
    • A—HUMAN NECESSITIES
    • A23—FOODS OR FOODSTUFFS; TREATMENT THEREOF, NOT COVERED BY OTHER CLASSES
    • A23C—DAIRY PRODUCTS, e.g. MILK, BUTTER OR CHEESE; MILK OR CHEESE SUBSTITUTES; PREPARATION THEREOF
    • A23C9/00—Milk preparations; Milk powder or milk powder preparations
    • A23C9/152—Milk preparations; Milk powder or milk powder preparations containing additives
    • A23C9/1528—Fatty acids; Mono- or diglycerides; Petroleum jelly; Paraffine; Phospholipids; Derivatives thereof
    • A—HUMAN NECESSITIES
    • A23—FOODS OR FOODSTUFFS; TREATMENT THEREOF, NOT COVERED BY OTHER CLASSES
    • A23C—DAIRY PRODUCTS, e.g. MILK, BUTTER OR CHEESE; MILK OR CHEESE SUBSTITUTES; PREPARATION THEREOF
    • A23C9/00—Milk preparations; Milk powder or milk powder preparations
    • A23C9/16—Agglomerating or granulating milk powder; Making instant milk powder; Products obtained thereby
    • A—HUMAN NECESSITIES
    • A23—FOODS OR FOODSTUFFS; TREATMENT THEREOF, NOT COVERED BY OTHER CLASSES
    • A23L—FOODS, FOODSTUFFS OR NON-ALCOHOLIC BEVERAGES, NOT OTHERWISE PROVIDED FOR; PREPARATION OR TREATMENT THEREOF
    • A23L2/00—Non-alcoholic beverages; Dry compositions or concentrates therefor; Preparation or treatment thereof
    • A23L2/52—Adding ingredients
    • A—HUMAN NECESSITIES
    • A23—FOODS OR FOODSTUFFS; TREATMENT THEREOF, NOT COVERED BY OTHER CLASSES
    • A23L—FOODS, FOODSTUFFS OR NON-ALCOHOLIC BEVERAGES, NOT OTHERWISE PROVIDED FOR; PREPARATION OR TREATMENT THEREOF
    • A23L33/00—Modifying nutritive qualities of foods; Dietetic products; Preparation or treatment thereof
    • A23L33/10—Modifying nutritive qualities of foods; Dietetic products; Preparation or treatment thereof using additives
    • A23L33/115—Fatty acids or derivatives thereof; Fats or oils
    • A—HUMAN NECESSITIES
    • A23—FOODS OR FOODSTUFFS; TREATMENT THEREOF, NOT COVERED BY OTHER CLASSES
    • A23L—FOODS, FOODSTUFFS OR NON-ALCOHOLIC BEVERAGES, NOT OTHERWISE PROVIDED FOR; PREPARATION OR TREATMENT THEREOF
    • A23L33/00—Modifying nutritive qualities of foods; Dietetic products; Preparation or treatment thereof
    • A23L33/10—Modifying nutritive qualities of foods; Dietetic products; Preparation or treatment thereof using additives
    • A23L33/115—Fatty acids or derivatives thereof; Fats or oils
    • A23L33/12—Fatty acids or derivatives thereof
    • A—HUMAN NECESSITIES
    • A23—FOODS OR FOODSTUFFS; TREATMENT THEREOF, NOT COVERED BY OTHER CLASSES
    • A23P—SHAPING OR WORKING OF FOODSTUFFS, NOT FULLY COVERED BY A SINGLE OTHER SUBCLASS
    • A23P10/00—Shaping or working of foodstuffs characterised by the products
    • A23P10/30—Encapsulation of particles, e.g. foodstuff additives
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/075—Ethers or acetals
    • A61K31/08—Ethers or acetals acyclic, e.g. paraformaldehyde
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/21—Esters, e.g. nitroglycerine, selenocyanates
    • A61K31/215—Esters, e.g. nitroglycerine, selenocyanates of carboxylic acids
    • A61K31/22—Esters, e.g. nitroglycerine, selenocyanates of carboxylic acids of acyclic acids, e.g. pravastatin
    • A61K31/221—Esters, e.g. nitroglycerine, selenocyanates of carboxylic acids of acyclic acids, e.g. pravastatin with compounds having an amino group, e.g. acetylcholine, acetylcarnitine
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/21—Esters, e.g. nitroglycerine, selenocyanates
    • A61K31/215—Esters, e.g. nitroglycerine, selenocyanates of carboxylic acids
    • A61K31/22—Esters, e.g. nitroglycerine, selenocyanates of carboxylic acids of acyclic acids, e.g. pravastatin
    • A61K31/23—Esters, e.g. nitroglycerine, selenocyanates of carboxylic acids of acyclic acids, e.g. pravastatin of acids having a carboxyl group bound to a chain of seven or more carbon atoms
    • A61K31/231—Esters, e.g. nitroglycerine, selenocyanates of carboxylic acids of acyclic acids, e.g. pravastatin of acids having a carboxyl group bound to a chain of seven or more carbon atoms having one or two double bonds
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/66—Phosphorus compounds
    • A61K31/662—Phosphorus acids or esters thereof having P—C bonds, e.g. foscarnet, trichlorfon
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/66—Phosphorus compounds
    • A61K31/683—Diesters of a phosphorus acid with two hydroxy compounds, e.g. phosphatidylinositols
    • A61K31/685—Diesters of a phosphorus acid with two hydroxy compounds, e.g. phosphatidylinositols one of the hydroxy compounds having nitrogen atoms, e.g. phosphatidylserine, lecithin
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K35/00—Medicinal preparations containing materials or reaction products thereof with undetermined constitution
    • A61K35/56—Materials from animals other than mammals
    • A61K35/60—Fish, e.g. seahorses; Fish eggs
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K8/00—Cosmetics or similar toiletry preparations
    • A61K8/18—Cosmetics or similar toiletry preparations characterised by the composition
    • A61K8/30—Cosmetics or similar toiletry preparations characterised by the composition containing organic compounds
    • A61K8/33—Cosmetics or similar toiletry preparations characterised by the composition containing organic compounds containing oxygen
    • A61K8/37—Esters of carboxylic acids
    • A61K8/375—Esters of carboxylic acids the alcohol moiety containing more than one hydroxy group
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K8/00—Cosmetics or similar toiletry preparations
    • A61K8/18—Cosmetics or similar toiletry preparations characterised by the composition
    • A61K8/30—Cosmetics or similar toiletry preparations characterised by the composition containing organic compounds
    • A61K8/40—Cosmetics or similar toiletry preparations characterised by the composition containing organic compounds containing nitrogen
    • A61K8/41—Amines
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K8/00—Cosmetics or similar toiletry preparations
    • A61K8/18—Cosmetics or similar toiletry preparations characterised by the composition
    • A61K8/30—Cosmetics or similar toiletry preparations characterised by the composition containing organic compounds
    • A61K8/55—Phosphorus compounds
    • A61K8/553—Phospholipids, e.g. lecithin
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P1/00—Drugs for disorders of the alimentary tract or the digestive system
    • A61P1/16—Drugs for disorders of the alimentary tract or the digestive system for liver or gallbladder disorders, e.g. hepatoprotective agents, cholagogues, litholytics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P11/00—Drugs for disorders of the respiratory system
    • A61P11/06—Antiasthmatics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P29/00—Non-central analgesic, antipyretic or antiinflammatory agents, e.g. antirheumatic agents; Non-steroidal antiinflammatory drugs [NSAID]
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P3/00—Drugs for disorders of the metabolism
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P3/00—Drugs for disorders of the metabolism
    • A61P3/02—Nutrients, e.g. vitamins, minerals
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P3/00—Drugs for disorders of the metabolism
    • A61P3/04—Anorexiants; Antiobesity agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P3/00—Drugs for disorders of the metabolism
    • A61P3/06—Antihyperlipidemics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P3/00—Drugs for disorders of the metabolism
    • A61P3/08—Drugs for disorders of the metabolism for glucose homeostasis
    • A61P3/10—Drugs for disorders of the metabolism for glucose homeostasis for hyperglycaemia, e.g. antidiabetics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P9/00—Drugs for disorders of the cardiovascular system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61Q—SPECIFIC USE OF COSMETICS OR SIMILAR TOILETRY PREPARATIONS
    • A61Q19/00—Preparations for care of the skin
    • G—PHYSICS
    • G01—MEASURING; TESTING
    • G01N—INVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
    • G01N30/00—Investigating or analysing materials by separation into components using adsorption, absorption or similar phenomena or using ion-exchange, e.g. chromatography or field flow fractionation
    • G01N30/02—Column chromatography
    • G—PHYSICS
    • G01—MEASURING; TESTING
    • G01N—INVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
    • G01N30/00—Investigating or analysing materials by separation into components using adsorption, absorption or similar phenomena or using ion-exchange, e.g. chromatography or field flow fractionation
    • G01N30/02—Column chromatography
    • G01N30/62—Detectors specially adapted therefor
    • G01N30/72—Mass spectrometers
    • A—HUMAN NECESSITIES
    • A23—FOODS OR FOODSTUFFS; TREATMENT THEREOF, NOT COVERED BY OTHER CLASSES
    • A23L—FOODS, FOODSTUFFS OR NON-ALCOHOLIC BEVERAGES, NOT OTHERWISE PROVIDED FOR; PREPARATION OR TREATMENT THEREOF
    • A23L33/00—Modifying nutritive qualities of foods; Dietetic products; Preparation or treatment thereof
    • A23L33/40—Complete food formulations for specific consumer groups or specific purposes, e.g. infant formula
    • A—HUMAN NECESSITIES
    • A23—FOODS OR FOODSTUFFS; TREATMENT THEREOF, NOT COVERED BY OTHER CLASSES
    • A23V—INDEXING SCHEME RELATING TO FOODS, FOODSTUFFS OR NON-ALCOHOLIC BEVERAGES AND LACTIC OR PROPIONIC ACID BACTERIA USED IN FOODSTUFFS OR FOOD PREPARATION
    • A23V2002/00—Food compositions, function of food ingredients or processes for food or foodstuffs
    • G—PHYSICS
    • G01—MEASURING; TESTING
    • G01N—INVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
    • G01N30/00—Investigating or analysing materials by separation into components using adsorption, absorption or similar phenomena or using ion-exchange, e.g. chromatography or field flow fractionation
    • G01N30/02—Column chromatography
    • G01N2030/022—Column chromatography characterised by the kind of separation mechanism
    • G01N2030/027—Liquid chromatography

Landscapes

  • Health & Medical Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • General Health & Medical Sciences (AREA)
  • Veterinary Medicine (AREA)
  • Public Health (AREA)
  • Animal Behavior & Ethology (AREA)
  • Medicinal Chemistry (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Engineering & Computer Science (AREA)
  • Diabetes (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Organic Chemistry (AREA)
  • General Chemical & Material Sciences (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Epidemiology (AREA)
  • Obesity (AREA)
  • Hematology (AREA)
  • Emergency Medicine (AREA)
  • Polymers & Plastics (AREA)
  • Food Science & Technology (AREA)
  • Nutrition Science (AREA)
  • Mycology (AREA)
  • Oil, Petroleum & Natural Gas (AREA)
  • Endocrinology (AREA)
  • Child & Adolescent Psychology (AREA)
  • Pulmonology (AREA)
  • Pediatric Medicine (AREA)
  • Birds (AREA)
  • Heart & Thoracic Surgery (AREA)
  • Cardiology (AREA)
  • Analytical Chemistry (AREA)
  • Biophysics (AREA)
  • Pathology (AREA)
  • Immunology (AREA)
  • Physics & Mathematics (AREA)
  • General Physics & Mathematics (AREA)
  • Biochemistry (AREA)
  • Gastroenterology & Hepatology (AREA)
JP2022503457A 2019-07-17 2020-07-17 ヒト対象の組織におけるエーテル脂質分子の混合物を維持または調節するための組成物 Active JP7890196B2 (ja)

Applications Claiming Priority (3)

Application Number Priority Date Filing Date Title
AU2019902527 2019-07-17
AU2019902527A AU2019902527A0 (en) 2019-07-17 Compositions and methods of use
PCT/AU2020/050742 WO2021007623A1 (en) 2019-07-17 2020-07-17 Compositions for maintaining or modulating mixtures of ether lipid molecules in a tissue of a human subject

Publications (3)

Publication Number Publication Date
JP2022541277A JP2022541277A (ja) 2022-09-22
JP2022541277A5 JP2022541277A5 (cg-RX-API-DMAC10.html) 2023-07-21
JP7890196B2 true JP7890196B2 (ja) 2026-07-14

Family

ID=74209622

Family Applications (1)

Application Number Title Priority Date Filing Date
JP2022503457A Active JP7890196B2 (ja) 2019-07-17 2020-07-17 ヒト対象の組織におけるエーテル脂質分子の混合物を維持または調節するための組成物

Country Status (10)

Country Link
US (1) US20220257616A1 (cg-RX-API-DMAC10.html)
EP (1) EP3999044A4 (cg-RX-API-DMAC10.html)
JP (1) JP7890196B2 (cg-RX-API-DMAC10.html)
KR (1) KR20220047775A (cg-RX-API-DMAC10.html)
CN (2) CN120360984A (cg-RX-API-DMAC10.html)
BR (1) BR112022000814A2 (cg-RX-API-DMAC10.html)
CA (1) CA3147249A1 (cg-RX-API-DMAC10.html)
IL (1) IL289859A (cg-RX-API-DMAC10.html)
MX (1) MX2022000664A (cg-RX-API-DMAC10.html)
WO (1) WO2021007623A1 (cg-RX-API-DMAC10.html)

Families Citing this family (5)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
CN115236170B (zh) * 2022-07-25 2024-11-26 清华大学 基于毛细管电泳的脂质组分析系统及其应用和脂质组的分析方法
WO2024148052A1 (en) 2023-01-03 2024-07-11 Baker Heart and Diabetes Institute Ether of phosphatidylcholine and phosphatidylethanolamine, their lyso-forms and mixture thereof for use in the treatment of treatment of a disease or disorder caused by a deficiency in plasmalogens
EP4661856A1 (en) * 2023-02-10 2025-12-17 Baker Heart and Diabetes Institute Plasmalogen modulation of immune cells
WO2026008605A2 (en) 2024-07-01 2026-01-08 Pelagic Ai Limited Chemical synthesis of bioactive precursors to plasmalogens
WO2026008716A1 (en) 2024-07-02 2026-01-08 Baker Heart and Diabetes Institute Methods of use for plasmalogen precursors in treating plasmalogen-associated diseases

Citations (10)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
WO2006024742A1 (fr) 2004-08-13 2006-03-09 Universite De Rennes 1 Complement alimentaire pour animaux d'elevage et procede de mise en œuvre de celui-ci
WO2008031917A1 (en) 2006-09-14 2008-03-20 Zora Biosciences Oy Biofluid metabolite profiling as a tool for early prediction of autoimmunity and type 1 diabetes risk
US20090131368A1 (en) 2006-07-19 2009-05-21 Su Chen Mixtures of and methods of use for polyunsaturated fatty acid-containing phospholipids and alkyl ether phospholipids species
WO2010100060A2 (en) 2009-03-04 2010-09-10 Nestec S.A. Method for increasing endogenous plasmalogen levels in mammals
WO2010136499A1 (de) 2009-05-27 2010-12-02 Kdg Mediatech Ag Optischer datenträger
WO2011036117A1 (en) 2009-09-22 2011-03-31 One Way Liver Genomics, S.L. Method for the diagnosis of non-alcoholic steatohepatitis based on a metabolomic profile
JP2012140385A (ja) 2011-01-06 2012-07-26 Nikko Chemical Co Ltd 水中油型乳化化粧料
WO2013113992A1 (en) 2012-01-31 2013-08-08 Teknologian Tutkimuskeskus Vtt Method for determining liver fat amount and method for diagnosing nafld
WO2016041013A1 (en) 2014-09-16 2016-03-24 Baker Idi Heart And Diabetes Institute Holdings Limited Glycerolipids and uses therefor
CN107080249A (zh) 2016-06-30 2017-08-22 健糖（北京）健康管理有限公司 一种供糖尿病人群食用的配方食品及其制备工艺

Family Cites Families (20)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
GB1029610A (en) 1965-04-08 1966-05-18 Shell Int Research Improvements in or relating to ethers
US4046914A (en) 1966-12-16 1977-09-06 Astra Nutrition Ab Therapeutically active substituted saturated and mono-and polyunsaturated alkyl-glycerylethers
JPS56133281A (en) 1980-03-21 1981-10-19 Kao Corp Preparation of glyceryl ether
US4613621A (en) 1981-09-18 1986-09-23 Hoerrmann Wilhelm Fatty aldehydes and acids in the treatment of neurological and inflammatory diseases
US4595681A (en) * 1984-10-26 1986-06-17 The United States Of America As Represented By The United States Department Of Energy Antihypertensive neutral lipid
SE8800182L (sv) 1988-01-21 1989-07-22 Kaernerud Lars Haelsoprod Anvaendning av alkylglycerol foer framstaellning av ett laekemedel
ATE318832T1 (de) 1990-06-11 2006-03-15 Gilead Sciences Inc Verfahren zur vervendung von nukleinsäureliganden
US5270163A (en) 1990-06-11 1993-12-14 University Research Corporation Methods for identifying nucleic acid ligands
US5840867A (en) 1991-02-21 1998-11-24 Gilead Sciences, Inc. Aptamer analogs specific for biomolecules
US6121245A (en) 1997-01-29 2000-09-19 Firshein; Richard N. Method of treating cancer using alkylglycerols in conjunction with chemotherapy
SE9701912D0 (sv) 1997-05-22 1997-05-22 Interhealth Ab Pharmaceutical composition and use thereof
US6242246B1 (en) 1997-12-15 2001-06-05 Somalogic, Inc. Nucleic acid ligand diagnostic Biochip
US20070191495A1 (en) 2004-01-16 2007-08-16 Fuji Oil Company, Limited Lipase inhibitor
WO2009050692A2 (en) * 2007-10-16 2009-04-23 Vascular Biogenics Ltd. Platelet-activating factor (paf) analogs and uses thereof
US8975299B2 (en) 2007-11-01 2015-03-10 Enzymotec Ltd. Lipid mixture for infant nutrition
FR2945951B1 (fr) 2009-05-26 2012-07-13 Polaris Composition d'akg et son utilisation pour la fabrication d'un medicament.
KR101787618B1 (ko) 2010-09-24 2017-10-18 후지노 브레인 리서치 가부시키가이샤 항중추신경계 염증제
CA2812178C (en) 2011-11-17 2014-11-04 Phenomenome Discoveries Inc. Methods for the synthesis of plasmalogens and plasmalogen derivatives, and therapeutic uses thereof
KR101639128B1 (ko) 2013-10-29 2016-07-13 울산대학교 산학협력단 플라스마로젠 전구체, 플라스마로젠 또는 플라스마로젠 유사체를 유효성분으로 함유하는 간질환 예방 또는 치료용 약학조성물
WO2015196250A1 (en) 2014-06-27 2015-12-30 Commonwealth Scientific And Industrial Research Organisation Lipid comprising docosapentaenoic acid

Patent Citations (10)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
WO2006024742A1 (fr) 2004-08-13 2006-03-09 Universite De Rennes 1 Complement alimentaire pour animaux d'elevage et procede de mise en œuvre de celui-ci
US20090131368A1 (en) 2006-07-19 2009-05-21 Su Chen Mixtures of and methods of use for polyunsaturated fatty acid-containing phospholipids and alkyl ether phospholipids species
WO2008031917A1 (en) 2006-09-14 2008-03-20 Zora Biosciences Oy Biofluid metabolite profiling as a tool for early prediction of autoimmunity and type 1 diabetes risk
WO2010100060A2 (en) 2009-03-04 2010-09-10 Nestec S.A. Method for increasing endogenous plasmalogen levels in mammals
WO2010136499A1 (de) 2009-05-27 2010-12-02 Kdg Mediatech Ag Optischer datenträger
WO2011036117A1 (en) 2009-09-22 2011-03-31 One Way Liver Genomics, S.L. Method for the diagnosis of non-alcoholic steatohepatitis based on a metabolomic profile
JP2012140385A (ja) 2011-01-06 2012-07-26 Nikko Chemical Co Ltd 水中油型乳化化粧料
WO2013113992A1 (en) 2012-01-31 2013-08-08 Teknologian Tutkimuskeskus Vtt Method for determining liver fat amount and method for diagnosing nafld
WO2016041013A1 (en) 2014-09-16 2016-03-24 Baker Idi Heart And Diabetes Institute Holdings Limited Glycerolipids and uses therefor
CN107080249A (zh) 2016-06-30 2017-08-22 健糖（北京）健康管理有限公司 一种供糖尿病人群食用的配方食品及其制备工艺

Non-Patent Citations (4)

* Cited by examiner, † Cited by third party
Title
Donald J. Hanahan et al.，Studies on the Structure of Glyceryl Ethers and the Glyceryl Ether Phospholipids of Bovine Erythrocytes，Biochemistry，1963年，2(4)，630-641
PARRI, A. et al.，"Alkylglycerols reduce serum complement and plasma vascular endothelial growth factor in obese individuals"，Inflammopharmacology，2016年，vol. 24，pages 127-131
Tommaso Iannitti et al.，An Update on the Therapeutic Role of Alkylglycerols，Mar. Drugs，2010年，8，2267-2300，DOI: 10.3390/md8082267
YU, H. et al.，"Breast milk alkylglycerols sustain beige adipocytes through adipose tissue macrophages"，The Journal of Clinical Investigation，2019年，vol. 129, no. 6，pages 2485-2499

Also Published As

Publication number Publication date
WO2021007623A1 (en) 2021-01-21
EP3999044A1 (en) 2022-05-25
BR112022000814A2 (pt) 2022-03-08
AU2020314798A1 (en) 2022-02-24
IL289859A (en) 2022-03-01
KR20220047775A (ko) 2022-04-19
JP2022541277A (ja) 2022-09-22
EP3999044A4 (en) 2023-10-18
CN114502149A (zh) 2022-05-13
US20220257616A1 (en) 2022-08-18
CN120360984A (zh) 2025-07-25
CA3147249A1 (en) 2021-01-21
MX2022000664A (es) 2022-05-18

Legal Events

Date Code Title Description
A521 Request for written amendment filed

Free format text: JAPANESE INTERMEDIATE CODE: A523

Effective date: 20230712

A621 Written request for application examination

Free format text: JAPANESE INTERMEDIATE CODE: A621

Effective date: 20230712

A131 Notification of reasons for refusal

Free format text: JAPANESE INTERMEDIATE CODE: A131

Effective date: 20241007

A601 Written request for extension of time

Free format text: JAPANESE INTERMEDIATE CODE: A601

Effective date: 20250107

A521 Request for written amendment filed

Free format text: JAPANESE INTERMEDIATE CODE: A523

Effective date: 20250307

A131 Notification of reasons for refusal

Free format text: JAPANESE INTERMEDIATE CODE: A131

Effective date: 20250527

A601 Written request for extension of time

Free format text: JAPANESE INTERMEDIATE CODE: A601

Effective date: 20250815

A521 Request for written amendment filed

Free format text: JAPANESE INTERMEDIATE CODE: A523

Effective date: 20251027

A131 Notification of reasons for refusal

Free format text: JAPANESE INTERMEDIATE CODE: A131

Effective date: 20251216

A601 Written request for extension of time

Free format text: JAPANESE INTERMEDIATE CODE: A601

Effective date: 20260316

A521 Request for written amendment filed

Free format text: JAPANESE INTERMEDIATE CODE: A523

Effective date: 20260430

TRDD Decision of grant or rejection written
A01 Written decision to grant a patent or to grant a registration (utility model)

Free format text: JAPANESE INTERMEDIATE CODE: A01

Effective date: 20260602

A61 First payment of annual fees (during grant procedure)

Free format text: JAPANESE INTERMEDIATE CODE: A61

Effective date: 20260702

R150 Certificate of patent or registration of utility model

Ref document number: 7890196

Country of ref document: JP

Free format text: JAPANESE INTERMEDIATE CODE: R150